Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Holding IDYA?
Track your performance easily
IDYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.17 - $47.74
Previous CloseN/A
Volume96.34K
Average Volume (3M)851.04K
Market Cap
$1.97B
Enterprise Value$1.83B
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Apr 01, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding86,431,800
10 Day Avg. Volume812,719
30 Day Avg. Volume851,037
Standard Deviation0.21
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)512.47
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue466.28
Enterprise Value/Gross Profit78.22
Enterprise Value/Ebitda-9.78
Forecast
1Y Price Target
$57.45Price Target Upside152.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
IDEAYA Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash runway guidance extends at least into 2028, highlighting financial stability and the ability to continue operations without immediate need for additional funding.
Licensing AgreementIDYA announced an exclusive license agreement with Jiangsu Hengrui Pharma for SHR-4849, a novel DLL3 targeted topo-I based ADC for treatment of SCLC and neuroendocrine solid tumors.
Pipeline DevelopmentThe company released new annual guidance and numerous incremental updates across its pipeline, showcasing ongoing progress and commitment to development.
Bears Say
Clinical UncertaintyIncreased clinical risk in the neoadjuvant setting, and a perceived lack of commitment to darovasertib in the adjuvant setting.
Drug Development RisksChallenges in the therapeutic window for IDE397 combined with AMG193 due to a long dose-escalation period.
Market CompetitionPotential competition from AURA's bel-sar in neoadjuvant patients with small tumors may impact Ideaya Biosciences' total addressable market.
---
Ownership Overview
0.89% Insiders
34.00% Mutual Funds
0.01% Other Institutional Investors
51.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDYA FAQ
What was IDEAYA Biosciences’s price range in the past 12 months?
IDEAYA Biosciences lowest stock price was $22.16 and its highest was $47.73 in the past 12 months.
What is IDEAYA Biosciences’s market cap?
IDEAYA Biosciences’s market cap is $1.97B.
When is IDEAYA Biosciences’s upcoming earnings report date?
IDEAYA Biosciences’s upcoming earnings report date is Apr 01, 2025 which is in 73 days.
How were IDEAYA Biosciences’s earnings last quarter?
IDEAYA Biosciences released its earnings results on Nov 04, 2024. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.648 by $0.048.
Is IDEAYA Biosciences overvalued?
According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued.
Does IDEAYA Biosciences pay dividends?
IDEAYA Biosciences does not currently pay dividends.
What is IDEAYA Biosciences’s EPS estimate?
IDEAYA Biosciences’s EPS estimate is -0.63.
How many shares outstanding does IDEAYA Biosciences have?
IDEAYA Biosciences has 86,431,800 shares outstanding.
What happened to IDEAYA Biosciences’s price movement after its last earnings report?
IDEAYA Biosciences reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.648. Following the earnings report the stock price went up 4.895%.
Which hedge fund is a major shareholder of IDEAYA Biosciences?
Among the largest hedge funds holding IDEAYA Biosciences’s share is Deerfield Management Company, LP. It holds IDEAYA Biosciences’s shares valued at 82M.
---
IDEAYA Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.45 (152.86% Upside)
$57.45 (152.86% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 22.1%
Last 30 Days ▲ 22.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.92%
12-Months-Change
Fundamentals
Return on Equity
-21.10%
Trailing 12-Months
Asset Growth
132.65%
Trailing 12-Months
Company Description
IDEAYA Biosciences
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
---
IDYA Stock 12 Month Forecast
Average Price Target
$57.45
▲(152.86% Upside)
Technical Analysis
Blueprint Medicines
―
Kura Oncology
―
Fate Therapeutics
―
Adverum Biotechnologies
―
Meiragtx Holdings
―
Voyager Therapeutics
―
Best Analysts Covering IDYA
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+39.37%
reiterated a buy rating 3 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +39.37% per trade.
---